Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 amp||cholangiocarcinoma||sensitive||Infigratinib||Case Reports/Case Series||Actionable||In a clinical case study, treatment with Truseltiq (infigratinib) resulted in stable disease for 3.9 months in a patient with cholangiocarcinoma with amplification of FGFR2 (PMID: 34250419).||34250419|
|FGFR2 amp||cholangiocarcinoma||sensitive||Infigratinib||Case Reports/Case Series||Actionable||In a Phase II trial, Truseltiq (infigratinib) treatment demonstrated manageable toxicity, and resulted in a 27% tumor size reduction in a patient with advanced cholangiocarcinoma harboring FGFR2 amplification (PMID: 29182496; NCT02150967).||29182496|
|PubMed Id||Reference Title||Details|
|(29182496)||Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.||Full reference...|
|(34250419)||Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations.||Full reference...|